Does UnitedHealthcare Cover Cialis?

How UnitedHealthcare Classifies Tadalafil on Its Formulary

UnitedHealthcare maintains multiple formulary lists across its commercial, employer-sponsored, and Medicare Advantage product lines. Generic tadalafil appears on the majority of these formularies, though the specific tier placement varies by plan. Understanding where your medication falls on the formulary directly affects what you pay at the pharmacy counter.

Commercial and Employer-Sponsored Plans

On most UHC commercial plans, generic tadalafil sits at Tier 2 (preferred brand) or Tier 3 (non-preferred). The 2023 UnitedHealthcare Prescription Drug List places tadalafil tablets in the "preferred" category for plans using the Standard or Premium formulary [1]. Copays at Tier 2 typically range from $20 to $50 per fill, while Tier 3 copays can reach $50 to $75. Brand-name Cialis, where still listed, often occupies Tier 3 or a specialty tier with higher cost-sharing.

Employer-sponsored plans through UHC can customize their drug benefits. Some employers exclude erectile dysfunction medications entirely, while others cover them with quantity limits. The American Urological Association (AUA) notes that "PDE5 inhibitors remain first-line pharmacotherapy for erectile dysfunction" and recommends that coverage decisions reflect this clinical guideline status [2].

Medicare Advantage and Part D

Medicare Part D plans, including those administered by UnitedHealthcare (AARP Medicare Rx), generally do not cover medications prescribed solely for erectile dysfunction. This exclusion stems from the Medicare Modernization Act of 2003, which specifically carved out ED drugs from Part D coverage [3]. There is one significant exception. Tadalafil 5 mg daily, when prescribed for benign prostatic hyperplasia (BPH) under ICD-10 code N40.1, may be covered because the FDA approved this indication in 2011 [4].

A 2019 analysis published in the Journal of Urology found that only 17.2% of Medicare Part D plans included any tadalafil formulation on their formularies, and nearly all of those restricted coverage to the BPH indication [5].

Prior Authorization Requirements for Cialis and Tadalafil

Prior authorization (PA) is one of the most common barriers patients face when filling a tadalafil prescription through UnitedHealthcare. The PA process exists to confirm that the medication is medically appropriate and that the patient meets specific clinical criteria before the plan agrees to pay.

What Triggers a Prior Authorization

UHC typically requires prior authorization for brand-name Cialis on all plan types. Generic tadalafil may or may not require PA depending on the plan. Common triggers include: first-time prescriptions for ED, doses above 20 mg, requests for quantities exceeding the plan's monthly limit, and prescriptions written by non-specialist physicians for younger patients.

The UnitedHealthcare Clinical Pharmacy Programs guideline for PDE5 inhibitors states that approval requires documentation of an erectile dysfunction diagnosis, confirmation that no contraindicated nitrate therapy is in use, and verification that the prescriber has reviewed cardiovascular risk [6]. Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, has stated: "The requirement for prior authorization on first-line ED therapies creates unnecessary delays in care for a condition with well-established, evidence-based treatment algorithms" [7].

How to Manage the PA Process

Your prescriber submits the PA request electronically or by fax. Standard requests receive a decision within 72 hours. Urgent requests, where the delay could seriously harm the patient, must be resolved within 24 hours per federal guidelines [8]. If the PA is denied, your prescriber receives a denial letter with the specific reason.

Successful PA submissions typically include: the patient's complete medication history showing they have not responded to (or cannot tolerate) lower-cost alternatives, recent lab work including testosterone levels if applicable, and a clear statement of the clinical indication with supporting ICD-10 codes.

What You Will Pay Out of Pocket

The actual cost of tadalafil through UnitedHealthcare depends on several intersecting factors: your plan's formulary tier, your deductible status, whether you have met your out-of-pocket maximum, and your pharmacy choice. Here is what to expect across common scenarios.

Copay Ranges by Plan Type

For a 30-day supply of generic tadalafil 5 mg (daily dosing), patients on UHC commercial plans with Tier 2 placement typically pay $15 to $35 after meeting their deductible. At Tier 3, that range increases to $40 to $75. Brand-name Cialis, if covered, can cost $75 to $150 per fill at higher tiers.

A 2022 study in the American Journal of Men's Health examined out-of-pocket costs for PDE5 inhibitors across major insurers and found that the median patient cost for generic tadalafil was $32 per month, compared to $127 for brand-name Cialis [9]. UnitedHealthcare's costs fell close to these national medians.

Strategies to Reduce Your Cost

Preferred pharmacy networks offer the lowest copays. UHC's OptumRx mail-order pharmacy often provides a 90-day supply for the cost of two monthly copays, saving roughly 33% over retail fills [10]. Patients can also apply manufacturer copay cards, though these are not valid for Medicare or Medicaid beneficiaries.

For patients whose plans do not cover tadalafil at all, GoodRx pricing for 30 tablets of generic tadalafil 5 mg typically falls between $15 and $45 at major retail pharmacies. This cash-pay option sometimes beats the insured copay, particularly for patients who have not yet met their deductible.

Coverage by Diagnosis: ED vs. BPH vs. Pulmonary Arterial Hypertension

The diagnosis code attached to your tadalafil prescription significantly affects whether UnitedHealthcare approves coverage. Tadalafil holds FDA approval for three distinct indications, and each one follows a different coverage pathway within UHC's system.

Erectile Dysfunction (ICD-10: N52.x)

Coverage for the ED indication exists on most commercial plans but is excluded from Medicare Part D. Quantity limits apply. Most UHC plans cap ED prescriptions at 6 to 12 tablets per 30-day period for as-needed dosing (10 mg or 20 mg tablets) [6]. The AUA's 2018 guideline on erectile dysfunction recommends PDE5 inhibitors as first-line therapy and notes that tadalafil's 36-hour duration of action offers a distinct advantage for patients who prefer spontaneity [2].

Benign Prostatic Hyperplasia (ICD-10: N40.x)

Tadalafil 5 mg daily for BPH symptoms receives the broadest coverage across all UHC plan types, including Medicare Advantage. The FDA approved this indication based on data from four randomized controlled trials involving over 1,500 men, which demonstrated statistically significant improvements in International Prostate Symptom Score (IPSS) compared to placebo [4]. In the key trial, tadalafil 5 mg reduced IPSS by 4.8 points compared to 2.2 points for placebo (P<0.001, N=581) [11].

Pulmonary Arterial Hypertension

Tadalafil 40 mg daily (marketed as Adcirca) for pulmonary arterial hypertension (PAH) follows specialty pharmacy protocols. UHC typically covers Adcirca under its specialty tier with prior authorization. The PHIRST trial (N=405) demonstrated that tadalafil 40 mg improved 6-minute walk distance by 33 meters compared to placebo at 16 weeks [12].

Step Therapy and Formulary Alternatives

UnitedHealthcare frequently uses step therapy protocols that require patients to try one or more lower-cost medications before approving a more expensive option. For erectile dysfunction, this system is relatively straightforward because generic sildenafil (Viagra's active ingredient) is the most common first-step requirement.

Typical Step Therapy Sequence

Most UHC step therapy programs require a trial of generic sildenafil before approving tadalafil. The clinical rationale is cost-based, not efficacy-based. Generic sildenafil 20 mg tablets (prescribed off-label from the pulmonary hypertension formulation) can cost as little as $3 to $10 per month. If sildenafil fails or causes intolerable side effects (headache, flushing, visual disturbances), the plan will generally approve tadalafil [6].

Dr. Tobias Kohler, a urologist at the Mayo Clinic, has noted: "Sildenafil and tadalafil work through the same PDE5 mechanism, but their pharmacokinetic profiles differ enough that failure with one does not predict failure with the other" [13]. This clinical reality supports the appeal process when step therapy is required.

Other PDE5 Inhibitors on UHC Formularies

UnitedHealthcare formularies also list vardenafil (generic Levitra) and avanafil (Stendra). Vardenafil typically sits at the same tier as tadalafil. Avanafil, still brand-only, usually occupies a higher tier or requires PA. A 2021 network meta-analysis in BJU International comparing all four PDE5 inhibitors found no statistically significant differences in overall efficacy, though tadalafil had the longest duration of action at 36 hours versus 4 to 6 hours for the others [14].

How to Appeal a Coverage Denial

If UnitedHealthcare denies coverage for tadalafil, you have the right to appeal. The appeals process follows a structured timeline, and understanding each step increases your chances of a successful outcome.

Internal Appeal

You or your prescriber must file the first-level internal appeal within 180 days of the denial notice. Include a letter of medical necessity from your physician, relevant clinical documentation (lab results, prior medication trials, symptom severity scores), and references to clinical guidelines supporting PDE5 inhibitor use. UHC must respond within 30 days for standard appeals or 72 hours for expedited appeals [8].

External Review

If the internal appeal is denied, you can request an independent external review. An outside physician reviewer examines the case without UHC involvement. Federal law under the Affordable Care Act guarantees this right for all fully insured plans [15]. The external reviewer's decision is binding on UHC.

Success rates for ED medication appeals vary. A 2020 analysis in Health Affairs found that 43% of first-level internal appeals for prescription drug denials across commercial insurers were overturned, and an additional 22% were reversed at external review [16].

Checking Your Specific UHC Plan Coverage

Because UnitedHealthcare administers hundreds of distinct plan designs, the most reliable way to confirm your tadalafil coverage is to check your individual benefit details.

Online and Phone Verification

Log into myuhc.com and manage to "Pharmacy" then "Look up a drug" to see your plan's formulary status for tadalafil. The tool shows tier placement, quantity limits, prior authorization requirements, and estimated copay. You can also call the number on the back of your UHC member ID card and ask the pharmacy benefits representative to run a test claim.

Questions to Ask Your Plan

When contacting UHC, ask these specific questions: Is generic tadalafil on my formulary, and at what tier? Does my plan require prior authorization or step therapy? What is my copay after deductible? Are there quantity limits? Is mail-order pricing available? Does my plan distinguish between the ED and BPH indications for coverage purposes?

The answers to these questions will give you a complete picture of your expected costs before you fill the prescription.

Tadalafil Dosing and Clinical Considerations Under UHC Coverage

The dose your physician prescribes affects both clinical outcomes and insurance coverage. UHC's formulary and quantity limit policies treat different tadalafil doses differently.

As-Needed Dosing (10 mg and 20 mg)

For erectile dysfunction, the standard starting dose is 10 mg taken before sexual activity, adjustable to 20 mg based on response and tolerability [4]. UHC typically limits these tablets to 6 to 12 per month. The FDA label recommends taking the dose at least 30 minutes before activity, with efficacy lasting up to 36 hours.

Daily Dosing (2.5 mg and 5 mg)

Daily tadalafil at 2.5 mg or 5 mg provides continuous PDE5 inhibition, eliminating the need to time doses around sexual activity. This regimen also treats BPH. A pooled analysis of 12 clinical trials (N=2,291) found that daily tadalafil 5 mg improved erectile function scores by a mean of 6.2 points on the IIEF-EF scale compared to 1.8 points for placebo [17]. UHC plans generally apply a 30-tablet monthly quantity limit for daily dosing, which aligns with the prescribed regimen.

Daily dosing at 5 mg for BPH carries an FDA-approved indication, which means UHC cannot classify it as an "ED drug" for exclusion purposes on Medicare Advantage plans. Physicians treating patients with both ED and BPH can use the N40.1 diagnosis code to access broader coverage for the same medication at the same dose.